文献速递糖尿病

减重术后糖尿病药物再启用的发生频率与预测因素

Baseline Diabetes Severity Is the Dominant Predictor of Diabetes Medication Re‐Initiation Following Bariatric Surgery
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-27

该回顾性队列研究利用映射至OMOP通用数据模型的电子健康记录数据,纳入2013—2026年间接受袖状胃切除术或Roux-en-Y胃旁路术的8012例患者,其中术前有2型糖尿病记录者2197例。2056例达到术后至少90天无药期并进入再启用风险集,其中882例(42.9%)后续重新启用降糖药。糖尿病病程、术前胰岛素使用、基线HbA1c与再启用风险升高相关,RYGB与风险降低相关。

要点

  • 减重术后达到至少90天无药期的患者中,42.9%后续重新启用降糖药,中位再启用时间为1.04年。
  • 糖尿病病程、术前胰岛素使用和基线HbA1c是再启用的主要预测因素,RYGB与较低风险相关。
  • 术后体重斜率和HbA1c斜率对再启用风险的判别改善有限。

核心结论

  • 减重术后达到无药状态的2型糖尿病患者中,超过40%在随访期间重新启用降糖药。
  • 再启用通常发生在达到无药状态后的早期,中位再启用时间为1.04年。

研究设计与样本

  • 回顾性队列研究,使用映射至OMOP通用数据模型的电子健康记录数据。
  • 纳入2013至2026年间接受袖状胃切除术或Roux-en-Y胃旁路术、术前有2型糖尿病的成年患者。
  • 患者达到术后至少90天无药期后进入再启用风险集,以Cox模型分析至首次降糖药再启用的时间。

主要发现

  • 8012例减重手术患者中,2197例(27.4%)术前有2型糖尿病记录;2056例(93.6%)达到术后至少90天无药期。
  • 2056例患者中882例(42.9%)后续重新启用降糖药,自风险集进入起中位再启用时间为1.04年(IQR 0.30–2.84)。
  • 糖尿病病程每增加1个SD,再启用HR为1.219(95% CI 1.152–1.289)。
  • 术前胰岛素使用与再启用风险升高相关,HR为1.627(95% CI 1.403–1.886)。
  • 基线HbA1c每增加1个SD,再启用HR为1.089(95% CI 1.030–1.151)。

临床怎么用

  • 可依据术前糖尿病病程、胰岛素使用、基线HbA1c和术式帮助识别再启用高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Bariatric surgery is highly effective for inducing remission of Type 2 diabetes mellitus (T2DM), yet the frequency and timing of diabetes medication re-initiation after achieving medication-free status are poorly characterized. Objective To estimate diabetes medication re-initiation after a postoperative medication-free interval and determine whether longitudinal postoperative weight and HbA1c trajectories provide incremental prognostic information beyond baseline diabetes severity. Methods We performed a retrospective cohort study using electronic health record data mapped to the OMOP Common Data Model. Adults with preoperative T2DM undergoing sleeve gastrectomy or Roux-en-Y gastric bypass between 2013 and 2026 were included. Patients entered the re-initiation risk set after achieving a postoperative medication-free interval of at least 90 days. Time to first subsequent diabetes medication restart was analysed using Cox models incorporating baseline clinical factors and longitudinal postoperative weight and HbA1c trajectories. Results Among 8012 unique patients undergoing bariatric surgery, 2197 (27.4%) had documented T2DM before the index operation. Of these, 2056 (93.6%) achieved a postoperative medication-free interval of at least 90 days and entered the re-initiation risk set; 882 (42.9%) subsequently re-initiated diabetes medication. Among patients who re-initiated therapy, median time to re-initiation from risk-set entry was 1.04 years (IQR, 0.30–2.84). In the primary Cox model, diabetes duration (HR: 1.219 per SD, 95% CI: 1.152–1.289), preoperative insulin use (HR: 1.627, 95% CI: 1.403–1.886) and baseline HbA1c (HR: 1.089 per SD, 95% CI: 1.030–1.151) were associated with increased medication re-initiation, whereas Roux-en-Y gastric bypass (RYGB) was associated with lower risk (HR: 0.778, 95% CI: 0.684–0.883). Age was not independently associated with re-initiation. Postoperative weight slope had a small association with re-initiation (HR: 1.042 per SD, 95% CI: 1.028–1.056; C-index = 0.6237). In the 1251-patient longitudinal HbA1c cohort, addition of HbA1c slope improved model fit (likelihood-ratio p = 0.0075) but provided little improvement in discrimination. Conclusions Diabetes medication re-initiation following bariatric surgery was common and occurred relatively early after achievement of medication-free status. More than 40% of patients re-initiated therapy during follow-up. This frequency exceeds rates reported in much of

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Baseline Diabetes Severity Is the Dominant Predictor of Diabetes Medication Re‐Initiation Following Bariatric Surgery

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。